Finn
GILD Biopharma · Large cap · HIV · Oncology · Thesis updated November 1, 2026

HIV strength battles looming Biktarvy price cuts

01 Running thesis

The HIV engine accelerates into a major test

Gilead's core HIV business is accelerating. In Q3 2026, base business revenue grew 16% year over year. The HIV franchise surged 18%, driven by strong demand for Biktarvy and the prevention drug Yeztugo.

But a major structural headwind is now quantified. Medicare set the 2028 negotiated price for Biktarvy at a 38% discount. Management expects this to create a $1.5 billion net revenue hit in 2028 across all government channels.

The company must offset that hit with growth in oncology and inflammation. The results are split. Trodelvy grew 42% year over year in Q3 2026, but the Cell Therapy franchise dropped 18% and faces new clinical holds in its pipeline.

The stock story is a race against time. Gilead has a massive cash engine in HIV and a pending FDA decision for its anito-cel blood cancer therapy. But it must execute flawlessly to outrun the coming 2028 price cuts and fix its struggling cell therapy business.

Oct 2026→Gilead reported strong Q3 2026 base business growth of 16% year over year, driven by HIV and Trodelvy. However, management warned that 2028 Medicare price cuts to Biktarvy will create a $1.5 billion revenue headwind.
Aug 2026→Gilead recorded $11.2 billion in research charges for acquisitions and a $1.75 billion impairment on Trodelvy. However, a major legal risk was resolved with a favorable court ruling in the TDF litigation.
Aug 2026▲The Q2 2026 report highlighted a $4 billion annual run rate for the HIV prevention business, pushing management to raise full-year HIV growth guidance. Cell Therapy sales fell 14% year over year, continuing to show weakness.
May 2026▲Gilead raised 2026 Yeztugo guidance to $1 billion and lifted expected HIV growth to about 8%. Cell Therapy remained the main weak spot, with Q1 2026 sales down 12% year over year.
May 2026▲The Q1 2026 filing showed HIV sales up 10% to $5.0 billion and Trodelvy sales up 37% to $402 million. It also confirmed new deal activity with Arcellx, Tubulis, and Ouro, which adds pipeline upside and integration risk.
Feb 2026→The 2025 Form 10-K added a better Biktarvy patent runway, with earliest U.S. generic entry for full dose Biktarvy set for April 1, 2036. The same filing highlighted 2028 Medicare price negotiation, 340B disputes, and counterfeit drug risk.
Feb 2026▲Management guided to about $800 million of 2026 Yeztugo revenue and about 6% HIV growth. The update also pointed to a roughly 10% 2026 decline for Kite, showing that oncology remained under pressure.
Nov 2025▼Gilead disclosed that the Phase 3 ASCENT-07 study for Trodelvy did not meet its main goal. That hurt confidence in the oncology diversification plan.
02 Business model

Patented drugs, concentrated cash flow

Gilead discovers, develops, and sells prescription medicines for serious diseases. Most revenue comes from patented drugs sold through wholesalers. That means pricing, patent life, insurance access, and doctor use matter heavily.

HIV is the main profit driver. Biktarvy leads in treatment, while Descovy and Yeztugo drive prevention. This franchise funds research, dividends, share repurchases, and acquisitions.

The risk is concentration. If HIV pricing falls, the whole company feels it. Oncology and inflammation are supposed to reduce that dependence, but the results remain mixed.

Gilead relies heavily on acquisitions to build its non-HIV pipeline. Buying outside science brings new drugs faster than internal research, but it adds integration risk and immense upfront costs.

03 Product portfolio

The drugs that matter most

Cash cow

Biktarvy

Biktarvy is Gilead's flagship HIV treatment. Medicare price negotiation will force a 38% discount starting in 2028.

Growth engine

Yeztugo

Yeztugo is a long-acting HIV prevention shot that is fueling higher franchise growth and hitting a $1 billion annual run rate.

Steady

Descovy and other HIV medicines

Descovy for prevention continues to grow, while Genvoya, Odefsey, and Symtuza support the broader HIV base.

Growth engine

Trodelvy

Trodelvy is the stronger part of Gilead's oncology portfolio right now. Q3 2026 sales were $506 million, up 42% year over year.

Option

Yescarta and Tecartus

These Cell Therapy products were meant to diversify Gilead. Q3 2026 sales were $355 million, down 18% year over year because of competition.

Steady

Livdelzi and liver disease drugs

Liver Disease sales were $927 million in Q3 2026, up 13% year over year, helped by the new primary biliary cholangitis drug Livdelzi.

Steady

Veklury

Veklury is Gilead's COVID-19 antiviral. Full year 2026 guidance is approximately $300 million due to lower hospitalizations.

04 Business segments

Q3 sales rely heavily on HIV

HIV77%growing fast
Liver Disease12%modest
Oncology11%flat

This mix uses Gilead's product group sales for the three months ended September 30, 2026. The listed product groups total just under reported product sales because of rounding.

05 Risk factors

What could go wrong

Biktarvy price cut in 2028

High impact · High odds

Medicare set a 38% discount for Biktarvy effective 2028. Management estimates a $1.5 billion net revenue headwind across all government channels.

We watchWatch for any changes to management's 2028 revenue estimates and operating margins.

Cell Therapy keeps losing share

Medium impact · High odds

Cell Therapy sales fell 18% year over year in Q3 2026. A partial clinical hold on the KITE-753 pipeline asset adds further pressure.

We watchWatch whether the year-over-year sales decline narrows and for FDA updates on KITE-753.

M&A becomes too much to digest

Medium impact · Medium odds

Gilead is using large deals to build oncology and inflammation. This adds massive integration costs and heightens the risk of distracting the team from the core HIV business.

We watchWatch for pipeline delays or unexpected deal-related charges in upcoming quarters.

Oncology pipeline disappoints again

Medium impact · Medium odds

Trodelvy is growing, but it took a $1.75 billion impairment charge in Q2 2026 for its lung cancer program. More failures would hurt the case that oncology can become a second growth pillar.

We watchWatch Phase 3 data from ASCENT-GYN around year-end 2026.

Drug channel and legal pressure

Medium impact · Medium odds

Gilead disclosed risks tied to counterfeit versions of its medicines and legal fights around the 340B drug pricing program. Counterfeits can hurt patients and trust.

We watchWatch for 340B court rulings and any new counterfeit drug disclosures.
06 Quick answers

In one breath

What does Gilead Sciences make?

Gilead makes prescription medicines for HIV, liver disease, cancer, inflammation, and viral infections. Its most important business is HIV, led by Biktarvy for treatment and Yeztugo and Descovy for prevention.

Why is Yeztugo important for Gilead?

Yeztugo is a twice-yearly HIV prevention shot, which makes it easier for some people than taking pills often. It is helping the prevention business reach a $1 billion annual run rate.

What is the biggest risk for Gilead stock?

The biggest risk is that Gilead depends heavily on HIV while Biktarvy faces a massive Medicare price cut in 2028. Management expects a $1.5 billion revenue headwind from this change.

Is Gilead growing outside HIV?

Yes, but the picture is mixed. Trodelvy grew 42% year over year in Q3 2026, while Cell Therapy sales fell 18% year over year because of intense competition.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Gilead Q3 2026 earnings transcript
  2. Gilead Q2 2026 Form 10-Q
  3. Gilead Q1 2026 Form 10-Q
08 Explore the industry

Comparable Drug Manufacturers - General companies

Companies near Gilead Sciences, Inc. in Finn's Drug Manufacturers - General industry ranking.

Get started with Finn today